The above button links to Coinbase. Yahoo Finance is not a broker-dealer or investment adviser and does not offer securities or cryptocurrencies for sale or facilitate trading. Coinbase pays us for ...
Investor's Business Daily on MSN
Nurix, Sanofi Diverge — And One Breaks Out — On A Shocking Eczema Development
Shares of Nurix Therapeutics crashed Wednesday after Sanofi unexpectedly scrapped an experimental eczema drug that two were ...
Sanofi has predicted that Dupixent will receive “the majority of the benefit” from the direct-to-consumer (DTC) marketing ca ...
The above button links to Coinbase. Yahoo Finance is not a broker-dealer or investment adviser and does not offer securities or cryptocurrencies for sale or facilitate trading. Coinbase pays us for ...
Lebrikizumab maintains stable skin and itch control through 3 years in most week 16 responders with moderate-to-severe atopic ...
Nektar gains a clearer path in atopic dermatitis after Sanofi halts amlitelimab development, removing a major competitor. NKTR's rezpegaldesleukin enters Phase 3 ZENITH AD trials, targeting both ...
In the SHORE phase 3 study, amlitelimab in combination with topical therapies met all primary and key secondary endpoints at Week 24 with efficacy progressively increasing throughout the treatment ...
Kymera Therapeutics, Inc. (NASDAQ:KYMR) on Monday revealed clinical results from the Phase 1 healthy volunteer study of KT-621, its first-in-class, oral STAT6 degrader medicine. The findings ...
Stocktwits on MSN
NRIX stock clocks worst day ever after Sanofi discontinues trial of licensed drug, Wells Fargo slashes price target
Wells lowered its price target on Nurix Therapeutics to $20 from $25 and maintained an Equal Weight rating on the shares.
Eingun James Song, MD, explains bone alkaline phosphatase trends and growth considerations in pediatric atopic dermatitis.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results